Table 1. Clinical characteristics of the... | American Society of Hematology

Table 1.

Clinical characteristics of the study population

Characteristics	Frequency n = 541	5 y OS	5 y DFS
LDH
≤ Normal	43%	73 ± 6%	61 ± 6%
> Normal	57%	64 ± 5%^*	56 ± 6%^*
Stage
Localized (I-II)	39%	76 ± 6%	66 ± 6%
Disseminated (III-IV)	61%	63 ± 5%^*	51 ± 6%^*
Performance status
0-1	80%	70 ± 5%	59 ± 6%
2-4	20%	62 ± 8%^†	53 ± 9%
IPI Score
0	15%	84 ± 8%	76 ± 10%
1	40%	70 ± 7%	58 ± 7%
2	35%	61 ± 8%	55 ± 8%
3	10%	58 ± 14%^*	47 ± 14%^*
Consolidative treatment
Sequential chemotherapy	50.5%	67 ± 6%	54 ± 7%
HDT with ASCT	49.5%	69 ± 6%	62 ± 6%

Characteristics	Frequency n = 541	5 y OS	5 y DFS
LDH
≤ Normal	43%	73 ± 6%	61 ± 6%
> Normal	57%	64 ± 5%^*	56 ± 6%^*
Stage
Localized (I-II)	39%	76 ± 6%	66 ± 6%
Disseminated (III-IV)	61%	63 ± 5%^*	51 ± 6%^*
Performance status
0-1	80%	70 ± 5%	59 ± 6%
2-4	20%	62 ± 8%^†	53 ± 9%
IPI Score
0	15%	84 ± 8%	76 ± 10%
1	40%	70 ± 7%	58 ± 7%
2	35%	61 ± 8%	55 ± 8%
3	10%	58 ± 14%^*	47 ± 14%^*
Consolidative treatment
Sequential chemotherapy	50.5%	67 ± 6%	54 ± 7%
HDT with ASCT	49.5%	69 ± 6%	62 ± 6%

Log-rank test:

P < .01;

†

P < .05.

ASCT indicates autologous stem cell transplantation; DFS, disease-free survival; HDT, high-dose therapy; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OS, overall survival.

View Large

This Feature Is Available To Subscribers Only